PHILLIPS 66 DL-,01/ US7185461040 /
8/9/2024 7:35:06 PM | Chg. +0.64 | Volume | Bid8:09:36 PM | Ask8:09:36 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
124.78EUR | +0.52% | 0 Turnover: 0.00 |
123.40Bid Size: 900 | 124.90Ask Size: 900 | 53.34 bill.EUR | - | - |
GlobeNewswire
7/1
Phillips Edison & Company Announces Appointment of Devin Murphy to Board of Directors
GlobeNewswire
6/27
Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Inte...
GlobeNewswire
6/25
FibroBiologics Announces Preliminary Proof of Concept for Novel Artificial Thymus Organoid Technolog...
GlobeNewswire
6/20
The International Food Information Council (IFIC) Releases Annual Food & Health Survey Revealing Ris...
GlobeNewswire
6/17
Phillips Edison & Company Inc. Invites You to Join Its Second Quarter 2024 Earnings Conference Call
GlobeNewswire
6/17
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire
6/12
Greystone Closes $22.9 Million in Total Debt Placement and Preferred Equity Financing for Fort Worth...
GlobeNewswire
6/5
EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference
GlobeNewswire
5/22
Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention
GlobeNewswire
5/20
Entero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease We...
GlobeNewswire
5/16
Optimal Daily Dairy Consumption Remains Elusive Despite Well-Established Health Benefits
GlobeNewswire
5/16
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)